Europe’s biosimilars market has delivered undeniable value and substantial savings, but its full promise remains unrealised.
In this article, we examine the barriers slowing adoption and explain how smarter regulation, incentives and reinvestment could accelerate patient access and unlock the next phase of growth. Removing the significant barriers that continue to limit their impact is essential.
KSR: Despite the progress made in biosimilars, many believe we’ve only scratched the surface of their potential. What’s holding the market back?
ME: The monumental progress that has already been made in biosimilars cannot be understated. During the last 20 years, biosimilars have transformed healthcare delivery throughout Europe, providing 6.9 billion patient treatment days and creating savings of €56 billion.1,2
That said, the full potential of biosimilars remains largely untapped, partially because of the protracted and complex clinical development process that they must undergo.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.